This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Patient Follow-up

Lawrence Jacobs, MD; Judith A. O'Malley, PhD; Arnold Freeman, MD; Roslyn Ekes; Peter A. Reese, JD

Arch Neurol. 1985;42(9):841-847.

Abstract
• Follow-up observations on patients with multiple sclerosis who were treated with human fibroblast interferon (interferon beta) administered intrathecally for six months revealed a persisting beneficial effect in terms of a reduction in exacerbation rates. At the time of our last report in 1982, ten interferon beta recipients had shown a reduction in their mean exacerbation rate from 1.8/yr before the study to 0.2 yr during the study while ten control patients with multiple sclerosis showed no change in their rates during the study (0.69/yr) compared with before it (0.68/yr). That report was based on observations made for means of 1.9 years in the recipients and 1.6 years in the controls. The recipient patients have now been followed up for 4.4 years (mean) and their exacerbation rates have continued to decrease to a current mean level of 0.16/yr. The control patients were "crossed over" and began receiving interferon beta intrathecally after they had been in the study for two years without showing any change in their rate. During the 2.0 years since crossover they also have shown a reduction in exacerbation rate to a mean of 0.30/yr. The toxic side effects of interferon beta administered intrathecally were acceptable in view of the benefit achieved. Interferon was identified in the cerebrospinal fluid (but not the serum) of two patients prior to treatment, which is probably a manifestation of de novo production of interferon by the central nervous system in response to the multiple sclerosis disease process.

Author Affiliations
From the Dent Neurologic Institute, Buffalo, NY (Dr. Jacobs and Ms Ekes); the Departments of Biological Resources (Dr O'Malley), Pediatric Oncology (Dr Freeman), and Biomathematics (Dr Reese), Roswell Park Memorial Institute, Buffalo, NY; and the Departments of Neurology and Physiology-Neurobiology (Dr Jacobs), Microbiology (Dr O'Malley), and Pediatrics (Dr Freeman), State University of New York School of Medicine at Buffalo.

Footnotes
Accepted for publication Nov 8, 1984.

Read in part before the World Conference of the International Federation of Multiple Sclerosis Societies, Zurich, Sept 15, 1984.

Reprint requests to Dent Neurologic Institute, Millard Fillmore Hospital, 3 Gates Circle, Buffalo, NY 14209 (Dr Jacobs).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cytomegalovirus InducesInterferon-Stimulated Gene Expression and Is Attenuated by Interferon in the Developing Brain
van den Pol et al.
J. Virol. 2007;81:332-348.
ABSTRACT | FULL TEXT  

A Brief History of the Use of Interferons as Treatment of Multiple Sclerosis
Jacobs and Johnson
Arch Neurol 1994;51:1245-1252.
ABSTRACT  

Systemic Interferon Alfa in Multiple Sclerosis-Reply
Panitch
Arch Neurol 1989;46:252-252.
ABSTRACT  

Intrathecally Administered Natural Human Fibroblast Interferon Reduces Exacerbations of Multiple Sclerosis: Results of a Multicenter, Double-blinded Study
Jacobs et al.
Arch Neurol 1987;44:589-595.
ABSTRACT  

Systemic {alpha}-Interferon in Multiple Sclerosis: Long-term Patient Follow-up
Panitch
Arch Neurol 1987;44:61-63.
ABSTRACT